Nothing Special   »   [go: up one dir, main page]

EP2234505B1 - Utilisation de la sphingomyéline et de glucides indigestibles pour améliorer la flore intestinale - Google Patents

Utilisation de la sphingomyéline et de glucides indigestibles pour améliorer la flore intestinale Download PDF

Info

Publication number
EP2234505B1
EP2234505B1 EP08865460A EP08865460A EP2234505B1 EP 2234505 B1 EP2234505 B1 EP 2234505B1 EP 08865460 A EP08865460 A EP 08865460A EP 08865460 A EP08865460 A EP 08865460A EP 2234505 B1 EP2234505 B1 EP 2234505B1
Authority
EP
European Patent Office
Prior art keywords
oligosaccharides
composition
use according
microbiota
months
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP08865460A
Other languages
German (de)
English (en)
Other versions
EP2234505A1 (fr
Inventor
Willem Ferdinand Nieuwenhuizen
Kaouther Ben Amor
Jan Knol
Eline Marleen Van Der Beek
Christopher Beermann
Gelske Speelmans
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nutricia NV
Original Assignee
Nutricia NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40801379&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP2234505(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nutricia NV filed Critical Nutricia NV
Priority to PL08865460T priority Critical patent/PL2234505T3/pl
Priority to EP08865460A priority patent/EP2234505B1/fr
Priority to EP13153122.0A priority patent/EP2589302B1/fr
Publication of EP2234505A1 publication Critical patent/EP2234505A1/fr
Application granted granted Critical
Publication of EP2234505B1 publication Critical patent/EP2234505B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733—Fructosans, e.g. inulin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
    • A23V2200/3202—Prebiotics, ingredients fermented in the gastrointestinal tract by beneficial microflora

Definitions

  • the present invention is in the field of nutritional compositions for restoring or maintaining a well balanced intestinal microbiota.
  • the composition is especially suitable for infants and toddlers.
  • the intestinal microbiota of breast-fed infants is primarily composed of species belonging to the genus Bifidobacterium and other lactic acid producing bacteria.
  • the microbiota of formula-fed infants is more diverse and contains in general more species belonging to Bacteroides, Clostridium and Enterobacteriaceae.
  • This difference in microbiota composition is alleged to result in many beneficial effects regarding the immune system, the gastro-intestinal barrier function and anti-pathogenic function, resulting in less gastro-intestinal infections in terms of both incidence and duration, less atopic diseases such as food allergy, atopic dermatitis, allergy induced asthma, and less constipation in breast-fed infants.
  • WO 2006/091103 discloses a composition comprising probiotics and two non-digestible saccharides for the use against several disorders.
  • WO 00/08948 discloses mixtures of non-digestible oligosaccharides and polysaccharides in order to improve the intestinal microbiota.
  • WO 2006/041316 discloses the use of sphingomyelin degradation products to decrease the amount of Clostridium difficile.
  • WO 2007/073194 discloses the use of compositions comprising phospholipids, sphingolipids and cholesterol and optionally non-digestible carbohydrates for use in prevention of obesity and/or diabetes.
  • the present invention is based on an unexpected advantageous effect of a composition comprising both sphingophospholipid and/or degradation products thereof, in particular ceramide, sphingoid base, sphingoid phosphate and/or lysosphingphospholipid, and non-digestible oligosaccharides comprising at least fructo-oligosaccharides and golacto-oligosaccharides on the composition and/or activity of the intestinal microbiota.
  • This combination surprisingly showed an enhanced favourable effect on the composition of the intestinal microbiota.
  • a decreased ratio of Firmicutes/Bacteroidetes, an increased ratio Bifidobactera total bacteria, and/or an increased prebiotic index was observed.
  • compositions comprising sphingophospholipid and/or degradation products thereof together with non-digestible carbohydrates comprising at least fructo-oligosaccharides and galacto-oligosaccharides, will, when administered early in life to infants and/or toddlers with an age below 36 months of age, beneficially affect the prevention of disorders, associated with a imbalanced intestinal microbiotia, for periods extending beyond the period when this composition is administered, i.e. above 36 months of age, such as childhood, adolescence and/or adulthood.
  • the present composition is particularly suitable for treating and/or preventing obesity. Since adipocytes, especially visceral adipocytes, are formed and proliferate during infancy, the present composition is especially suitable for administration to human subjects with an age below 36 months for prevention of obesity when said human subject has reached an age above 36 month of age.
  • sphingophospholipids and/or degradation product(s) thereof with non-digestible carbohydrate is particularly advantageous for use in treatment and/or prevention of disorders related to the intestinal microbiota composition, such as gastro-intestinal infections, diarrhoea, gastro-intestinal inflammation and/or constipation.
  • the present combination also can be used for treatment and/or prevention of atopic diseases such as allergy, more particularly food allergy, atopic dermatitis, allergy induced asthma, and systemic and respiratory infections.
  • atopic diseases such as allergy, more particularly food allergy, atopic dermatitis, allergy induced asthma, and systemic and respiratory infections.
  • the present invention concerns the use of a nutritional composition
  • a nutritional composition comprising
  • the present the present invention can also be worded as a nutritional composition comprising
  • the present composition comprises non-digestible carbohydrates.
  • Non-digestible carbohydrates improve the microbiota.
  • Non-digestible carbohydrates stimulate the growth and/or activity of bifidobacteria and bacteroides.
  • administration of non-digestible carbohydrates was found to advantageously decrease the ratio of FinnicutesBacteroidetes, i.e. clostridia/bacteroides.
  • the present composition comprises non-digestible carbohydrate with a DP between 2 and 250, more preferably 2 to 60.
  • the non-digestible carbohydrate comprises at least fructo-oligosaccharides (including inulin) and galacto-oligosaccharides (including transgalacto- oligosaccharides or beta-galacto-oligosaccharides).
  • Non-digestible carbohydrates include gluco-oligosaccharides (including gentio-, nigero- and cyclodextrin-oligosaccharides and polydextrose), arabino-oligosaccharides, mannan-oligosaccharides, xylo- oligosaccharides, fuco-oligosaccharides, arabinogalacto-oligosaccharides (including gum acacia), glucomanno-oligosaccharides, galactomanno-oligosaccharides (including partially hydrolysed guar gum), sialic acid comprising oligosaccharides and uronic acid oligosaccharides (including galacturonic acids and pectin degradation products).
  • gluco-oligosaccharides including gentio-, nigero- and cyclodextrin-oligosaccharides and polydextrose
  • arabino-oligosaccharides including gentio-
  • the present composition comprises fructo-oligosaccharides, galacto-oligosaccharides and galacturonic acid oligosaccharides.
  • the galacto-oligosaccharides are most preferably betagalacto-oligosaccharides.
  • the composition comprises galacto-oligosaccharides.
  • the galacto-oligosaccharide is preferably selected from the group consisting of beta-galacto-oligosaccharides, lacto-N-tetraose (LNT), lacto-N-neotetraose (neo-LNT), fucosyl-lactose, fucosylated LNT and fucosylated neo-LNT.
  • the present composition comprises beta-galacto-oligosaccharides.
  • Beta-galacto-oligosaccharides as used in the present invention refers to oligosaccharides composed of over 50%, preferably over 65% galactose units based on monomeric subunits, with a degree of polymerization (DP) of 2 to 20, in which at least 50%, more preferably at least 75%, even more preferably at least 90%, of the galactose units are linked together via a beta-glycosidic linkage, preferably a beta-1,4 glycosidic linkage.
  • the average DP is preferably of 3 to 6.
  • a glucose unit may be present at the reducing end of the chain of galactose units.
  • Beta-galacto-oligosaccharides are sometimes also referred to as transgalacto-oligosacchariodes (TOS).
  • TOS transgalacto-oligosacchariodes
  • a suitable source of beta-galacto-ologosaccharides is Vivinal®GOS (commercially available from Borculo Domo Ingredients, Zwolle, Netherlands).
  • Other suitable sources are Oligomate (Yakult), Cupoligo, (Nissin) and Bi2muno (Classado).
  • the composition comprises fructo-oligosaccharides.
  • Fructo-oligosaccharide as used in the present invention refers to carbohydrates composed of over 50%, preferably over 65 % fructose units based on monomeric subunits, in which at least 50%, more preferably at least 75%, even more preferably at least 90%, of the fructose units are linked together via a beta-glycosidic linkage, preferably a beta-2,1 glycosidic linkage.
  • a glucose unit may be present at the reducing end of the chain of galactose units.
  • the fructo-oligosaccharide has a DP or average DP of 2 to 250, more preferably 2 to 100, even more preferably 10 to 60.
  • Fructo-oligosaccaride comprises levan, hydrolysed levan, inulin, hydrolysed inulin, and synthesised fructo-oligosaccharides.
  • the composition comprises short chain fructo-oligosaccharides with an average degree of polymerization (DP) of 3 to 6, more preferably hydrolysed inulin or synthetic fructo-oligosaccharide.
  • DP degree of polymerization
  • the composition comprises long chain fructan with an average DP above 20, such as RaftilinHP.
  • the composition comprises both short chain and long chain fructan.
  • Fructo-oligosaccharide suitable for use in the compositions is also readily commercially available, e.g. RaftilineHP (Orafti).
  • the present composition preferably comprises uronic acid oligosaccharides, more preferably galacturonic acid oligosaccharides.
  • galacturonic acid oligosaccharide refers to an oligosaccharide wherein at least 50% of the monosaccharide units present in the oligosaccharide is galacturonic acid.
  • the galacturonic acid oligosaccharides used in the invention are preferably prepared from degradation of pectin, pectate, and/or polygalacturonic acid.
  • the degraded pectin is prepared by hydrolysis and/or beta-elimination of fruit and/or vegetable pectins, more preferably apple, citrus and/or sugar beet pectin, even more preferably apple, citrus and/or sugar beet pectin degraded by at least one lyase.
  • at least one of the terminal galacturonic acid units of the galacturonic acid oligosaccharide has a double bond.
  • the double bond effectively protects against attachment of pathogenic bacteria to intestinal epithelial cells.
  • one of the terminal galacturonic acid units comprises a C 4 -C 5 double bond.
  • the galacturonic acid oligosaccharide can be derivatised.
  • the galacturonic acid oligosaccharide may be methoxylated and/or amidated.
  • the galacturonic acid oligosaccharides are characterised by a degree of methoxylation above 20%, preferably above 50% even more preferably above 70%.
  • the composition comprises a mixture of inulin and fructo-oligosaccharides.
  • the composition comprises a mixture of galacto- oligosaccharides and a fructo-oligosaccharides selected from the group consisting of short chain fructo-oligosaccharides and inulin, more preferably inulin.
  • a mixture of at least two different non-digestible carbohydrates advantageously stimulates the beneficial bacteria of the intestinal microbiota to a greater extent than based on the single non-digestible carbohydrates.
  • the weight ratio between the mixture of two different non-digestible carbohydrates, preferably galacto-oligosaccharides and fructo-oligosaccharide is between 20 and 0.05, more preferably between 20 and 1.
  • Galacto-oligosaccharides are more pronounced to the human milk oligosaccharides.
  • the present composition comprises galacto-oligosaccharides with a DP of 2-10 and/or fructo-oligosaccharides with a DP of 2-60. These combination was found to synergistically increase bifidobacteria and lactobacilli.
  • the composition comprises beta-galacto-oligosaccharide, fructo-oligosaccharide and a pectin degradation product.
  • the presence of these three non-digestible oligosaccharides even further stimulates the bifidobacteria, while decreasing bacteroides and clostridia compared to galacto-oligosaccharides with fructan.
  • the weight ratio transgalacto-oligosaccharide : fructo-oligosaccharide : pectin degradation product is preferably (20 to 2) : 1 : (1 to 20), more preferably (12 to 7) : 1 : (1 to 3).
  • the composition comprises of 80 mg to 2 g non-digestible oligosaccharides per 100 ml, more preferably 150 mg to 1.50 g, even more preferably 300 mg to 1 g.
  • the composition preferably comprises 0.25 wt.% to 5.5 wt.%, more preferably 0.5 wt.% to 4 wt.%, even more preferably 1.5 wt.% to 3 wt.%.
  • a lower amount of non-digestible oligosaccharides will be less effective in stimulating the beneficial bacteria in the microbiota, whereas a too high amount will result in side-effects of bloating and abdominal discomfort.
  • the present composition comprises sphingophospholipids and/or one of its degradation products.
  • sphingophospholipid as in the present invention relates to a type of sphingolipid consisting of a sphingoid base bonded to one fatty acid via an amide bond and, via an oxygen, to one polar headgroup comprising a phosphate (phosphate, phosphocholine, phosphoserine, phosphoethanolamine, phosphoglycerol, or phosphoinositol).
  • a degradation product derived from sphingophospholipid, particularly ceramides, lysosphingophospholipid, sphingoid phosphate and/or the free sphingoid base is present in the composition.
  • Sphingoid bases in the present invention are preferably 2-amino-1,3-dihydroxy-alkanes or alkenes with ( 2S,3R ) -erythro stereochemistry, with a chain length of 14 atoms or higher.
  • Sphingoid bases may comprise three instead of two hydroxyl groups.
  • the aliphatic chains may be mono- or poly-unsaturated (in the cis- or trans-configuration) or saturated.
  • the aliphatic chain may be branched.
  • Sphingoid bases include sphingosine, sphinganine, phytosphingosine and dihydrophytosphingosine.
  • the composition comprises sphingomyelin.
  • Sphingomyelin is ceramide phosphorylcholine.
  • Ceramide consists of a sphingoid base linked to a fatty acid via an amide bond.
  • sphingophospholipids and/or degradation products thereof in particular lysosphingolipid, ceramide, sphingoid phosphate and/or sphingoid base, has a reducing effect on unfavourable bacteria in the intestinal microbiota, such as firmicutes, especially clostridia. Having both a stimulator of beneficial bacteria and an inhibitor of unfavourable bacteria present will improve the composition of the microbiotia and/or keep the microbiota well balanced in a much more effective way.
  • the composition comprises 10 to 200 mg sphingomyelin per 100 ml, more preferably 20 mg to 150 mg, even more preferably 60 mg to 100 mg.
  • the composition preferably comprises 0.25 wt.% to 5.5 wt.%, more preferably 0.5 wt.% to 4 wt.%, even more preferably 1.5 wt.% to 3 wt.%.
  • the composition preferably comprises 0.07 wt.% to 1.5 wt.%, more preferably 0.15 wt.% to 1.1 wt.%, even more preferably 0.5 wt.% to 0.8 wt.%.
  • a suitable source of sphingophospholipid is milk fat, more suitable butter milk fat or butter serum fat, egg yolk and/or soy lecithin.
  • the weight ratio between non-digestible oligosaccharides and sphingomyelin is between 0.4 and 200, more preferably between 1 and 75, even more preferably between 3 and 15. Having this ratio present in the composition ensures a balance between the stimulating effect on beneficial bacteria in the microbiota and a reducing effect on unfavourable bacteria in the microbiota.
  • LA refers to linoleic acid (18:2 n6)
  • ALA refers to alpha-linolenic acid (18:3 n3)
  • LC-PUFA refers to long chain polyunsaturated fatty acids and/or acyl chains comprising at least 20 carbon atoms in the fatty acyl chain and with 2 or more unsaturated bonds
  • DHA refers to docosahexaenoic acid (22:6, n3)
  • EPA refers to eicosapentaenoic acid (20:5 n3)
  • ARA refers to arachidonic acid (20:4 n6)
  • DPA refers to docosapentaenoic acid (22:5 n3).
  • LA preferably is present in a sufficient amount in order to promote a healthy growth and development, yet in an amount as low as possible to prevent occurrence of obesity later in life.
  • the composition therefore preferably comprises less than 15 wt.% LA based on total fatty acids, preferably between 5 and 14.5 wt.%, more preferably between 6 and 12 wt.%.
  • ALA is present in a sufficient amount to promote a healthy growth and development.
  • the present composition therefore preferably comprises at least 1.0 wt.% based on total fatty acids.
  • the composition comprises at least 1.6 wt.% ALA based on total fatty acids, more preferably at least 2.0 wt.%.
  • the composition comprises less than 10 wt.% ALA, more preferably less than 5.0 wt.% based on total fatty acids.
  • the weight ratio LA/ALA should be well balanced in order to prevent obesity, especially central obesity, while at the same time ensuring a normal growth and development. Therefore, the present composition preferably comprises a weight ratio of LA/ALA between 2 and 15, more preferably between 2 and 7, more preferably between 3 and 6, even more preferably between 4 and 5.5, even more preferably between 4 and 5.
  • the present composition comprises LC-PUFA, since LC-PUFA reduce obesity later in life, more preferably central obesity. More preferably, the present composition comprises n-3 LC-PUFA, even more preferably EPA, DPA and/or DHA, even more preferably DHA. It was found that these n-3 LC-PUFA decrease obesity. Since a low concentration of DHA, DPA and/or EPA is already effective and normal growth and development are important, the content of n-3 LC-PUFA in the present composition, preferably does not exceed 15 wt.% of the total fatty acid content, preferably does not exceed 10 wt.%, even more preferably does not exceed 5 wt.%.
  • the present composition comprises at least 0.2 wt%, preferably at least 0.5 wt.%, more preferably at least 0.75 wt.%, n-3 LC-PUFA of the total fatty acid content.
  • the weight ratio n-6 LC-PUFA / n-3 LC-PUFA in the present composition is preferably low in order to prevent obesity later in life.
  • the composition comprises a weight ratio of n-6 LC-PUFA / n-3 LC-PUFA below 1.5, more preferably below 1.0, even more preferably below 0.6.
  • LC-PUFA have the further advantage that they facilitate the adhesion of beneficial bacteria, thereby further improving the microbiota and/or maintaining a well balanced microbiota.
  • the present composition comprises cholesterol and/or cholesterylester.
  • the simultaneous presence of sphingophospholipid and cholesterol and/or cholesterylester in the composition delays the digestion of the sphingophospholipid in the small intestine, thereby increasing the amounts of sphingophospholipid which reaches the large intestine and hence the activity of sphingophospholipid and/or degradation products thereof against unfavourable bacteria in the intestinal microbiota.
  • the present composition preferably comprises at least 0.005 wt.% cholesterol and/or cholesterylester based on total fat, more preferably at least 0.01 wt.%, more preferably at least 0.05 wt.%, even more preferably at least 0.1 wt.%.
  • the amount of cholesterol and/or cholesteryester does not exceed 10 wt.% based on total lipid, more preferably does not exceed 5 wt.%, even more preferably does not exceed I wt.% of total lipid. Most preferably the amount of cholesterol is 0.5 to 0.7 wt.% based on total lipid.
  • the present composition is preferably orally administered. Degradation of the sphingophospholipid by the digestive enzymes is necessary to improve its action against unfavourable bacteria in the intestinal microbiota.
  • the present composition is preferably a nutritional formula, preferably an infant formula.
  • the present composition comprising non-digestible carbohydrates and sphingophospholipids and/or degradation products thereof is not human milk.
  • the present composition can advantageously be applied as a complete nutrition for infants.
  • the present composition preferably comprises lipid, protein and digestible carbohydrate and is preferably administered in liquid form.
  • the present invention includes dry food (e.g. powders) which is accompanied with instructions as to mix said dry food mixture with a suitable liquid (e.g. water).
  • the present invention advantageously provides a composition wherein the lipid provides 5 % to 50 % of the total calories.
  • the present invention advantageously provides a composition wherein the protein provides 5 % to 50 % of the total calories.
  • the present invention advantageously provides a composition wherein the digestible carbohydrate provides 15 % to 90% of the total calories.
  • the present invention advantageously provides a composition wherein the lipid provides 5 % to 50 % of the total calories, the protein provides 5 % to 50 % of the total calories, and the digestible carbohydrate provides 15 % to 90% of the total calories.
  • the lipid provides 35 % to 50% of the total calories
  • the protein provides 7.5 % to 12.5% of the total calories
  • the digestible carbohydrate provides 40 % to 55% of the total calories.
  • Total calories relates to the sum of the calories provided by the lipid, the digestible carbohydrate and the protein.
  • the protein used in the nutritional preparation is preferably selected from the group consisting of non-human animal proteins (preferably milk proteins), vegetable proteins (preferably soy protein and/or rice protein), free amino acids and mixtures thereof.
  • the present composition preferably contains casein, whey, hydrolysed casein and/or hydrolysed whey protein.
  • the protein comprises intact proteins, more preferably intact bovine whey proteins and/or intact bovine casein proteins.
  • the protein of is preferably selected from the group consisting of hydrolysed milk protein.
  • the present composition preferably contains digestible carbohydrate selected from the group consisting of sucrose, lactose, glucose, fructose, corn syrup solids, starch and maltodextrins, more preferably lactose.
  • the present composition comprises nucleotides and/or nucleosides, more preferably nucleotides.
  • the composition comprises cytidine 5'-monophospate, uridine 5'-monophospate, adenosine 5'-monophospate, guanosine 5'-monophospate, and/or inosine 5'-monophospate, more preferably cytidine 5'-monophospate, uridine 5'-monophospate, adenosine 5'-monophospate, guanosine 5'-monophospate, and inosine 5'-monophospate.
  • the composition comprises 5 to 100 mg, more preferably 5 to 50 mg, most preferably 10 to 50 mg nucleotides and/or nucleosides per 100 g dry weight of the composition.
  • the presence of nucleotides and/or nucleotides advantageously lowers the ratio of the bacteroides, porphyromonas and/or prevotella group to bifidobacteria.
  • nucleotides and/or nucleosides are deemed to act synergistically with the other ingredients of the present composition.
  • Stool irregularities e.g. hard stools, insufficient stool volume, diarrhoea
  • Stool irregularities e.g. hard stools, insufficient stool volume, diarrhoea
  • stool problems may be reduced by administering the present composition in a liquid form with an osmolality between 50 and 500 mOsm/kg, more preferably between 100 and 400 mOsm/kg.
  • the reduced stool irregularities enhance the colonization and development of a healthy intestinal microbiota.
  • the liquid food does not have an excessive caloric density, however still provides sufficient calories to feed the subject.
  • the liquid food preferably has a caloric density between 0.1 and 2.5 kcal/ml, even more preferably a caloric density of between 0.5 and 1.5 kcal/ml, most preferably between 0.6 and 0.8 kcal/ml.
  • the present composition comprising sphingophospholipids and/or degradation products thereof, preferably sphingomyelin, and a non-digestible carbohydrate comprising at least fructo-oligosaccharides and galato-oligosaccharides is particularly suitable for use in a human subject having an age below 36 months for use in normalising the composition of the intestinal microbiota.
  • the present composition is particularly suitable for use in a human subject having an age below 36 month for use in normalising the composition of the intestinal microbiota when said human subject has reached an age above 36 months.
  • Normalising the intestinal microbiota in the present human subjects below 36 months of age relates to normalising of the composition of the intestinal microbiota towards the composition found in the intestinal microbiota of healthy human milk fed human subjects with an age below 36 months.
  • the use in a human subject having an age below 36 months for use in normalising the composition of the intestinal microbiota when said human subject has reached an age above 36 months relates to normalising of the composition of the intestinal microbiota towards the composition found in the intestinal microbiota of healthy subjects of the same age which have been human milk fed in the past when they were of an age below 36 months.
  • the present composition comprising sphingophospholipid and/or degradation products thereof, preferably sphingomyelin, and a non-digestible carbohydrate comprising at least fructo-oligosaccharides and galocto-oligosaccharides is particularly suitable for use in a human subject having an age above 36 months for use in normalising the composition of the intestinal microbiota.
  • Normalising the intestinal microbiota in human subjects above 36 months of age relates to normalising of the composition of the intestinal microbiota towards the composition found in the intestinal microbiota of healthy human subjects of normal weight.
  • the present composition comprising sphingophospholipid and/or degradation products thereof, preferably sphingomyelin, and a non-digestible carbohydrate comprising at least fructo-oligosaccharides and galocto-oligosaccharides is particularly suitable for use in an obese human subject for use in normalising the composition of the intestinal microbiota.
  • Normalising the intestinal microbiota in obese human subjects relates to normalising of the composition of the intestinal microbiota towards the composition found in the intestinal microbiota of healthy human subjects with normal weight.
  • the present composition comprising sphingophospholipid and/or degradation products thereof, preferably sphingomyelin, and a non-digestible carbohydrate is particularly suitable for use in a human subject using or having recently used antibiotics for use in normalising the composition of the intestinal microbiota.
  • the term 'recently' in the context of the present invention refers to ending the use of antibiotics less than 2 months ago, for example less than 1 month ago or less than I week ago.
  • Normalising the intestinal microbiota in human subjects using or having recently used antibiotics relates to normalising of the composition of the intestinal microbiota towards the composition found in the intestinal microbiota of said human subjects compared to the period before antibiotic use or compared to the composition found in the intestinal microbiota.
  • Normalising the intestinal microbiota in the present invention in particular relates to an increased prebiotic index, an increased ratio Bifidobacteria / total bacteria, a decreased ratio Firmicutes/Bacteroidetes. Increase or decrease is with respect to the ratio present in the human subject prior to ingestion of the present composition, or to a control group not taking this composition.
  • the prebiotic index (PI) relates to the sum of: ( Bifidobacteria / total bacteria) + ( Lactobacilliltotal bacteria)- ( Bacteroides / total bacteria) - (Clostridia / total bacteria), see Palframan et al, 2003, Lett Appl Microbiol 37:281-284 .
  • the ratio of Eubacterium rectale/total bacteria may be added to this, more particularly for adults. Eubacterium rectale produces butyrate which is advantageous for the gut barrier in adults.
  • the intestinal microbiota relates in particular to the microbiota composition of the colon.
  • the composition of the intestinal microbiota can be determined on the level phylum, class, family, genus and/or species by methods known in the art, including FISH, real time PCR and micro-arrays, using specific probes and/or primers known in the art.
  • the present composition is especially advantageous for infants born in the hospital, since they are at risk of being colonised by unfavourable bacteria deriving from the hospital environment.
  • the present composition is even more advantageous for infants delivered via caesarean section, since these infants lack a proper inoculation with beneficial bacteria deriving from the mother, while at the same time they are at risk of being colonised by unfavourable bacteria deriving from the hospital environment.
  • the present composition is preferably subsequently used for the prevention and/or treatment of obesity and/or adiposity, more preferably visceral obesity, more preferably when said human subject has reached an age above 36 months.
  • the present composition preferably is used to prevent secondary disorders resulting from visceral obesity, such as type 2 diabetes, fasting hyperglycaemia, insulin resistance, visceral adiposity, hyperinsulinemia, hypertension, cardiovascular disease, cerebrovascular disease, artherosclerose, dyslipidaemia, hyperuricaemia, fatty liver, osteoarthritis and sleep apnoea when said human subject has reached an age above 36 months.
  • obesity, adiposity and visceral obesity refer to said conditions as the consequence of unbalanced intestinal microbiota.
  • unbalanced microbiota refers to an increased ratio of Firmicutes/Bacteroidetes, an increased ratio Clostridium pulposus /total bacteria, and/or a decreased prebiotic index compared to healthy lean subjects and/or to breast-fed infants.
  • the present composition is preferably subsequently used for the treatment and/or prevention of gastrointestinal infection, diarrhoea and/or gastrointestinal inflammation, more preferably when said human subject has reached an age above 36 months.
  • the present composition is preferably subsequently used for improving the immune system and/or the gastro-intestinal barrier function, more preferably when said human subject has reached an age above 36 months.
  • the present composition is preferably subsequently used for treatment and/or prevention of at least one disorder selected form the group consisting of allergy, asthma, atopic dermatitis, eczema, systemic infections, urinary tract infections, otitis and respiratory infections, more preferably when said human subject has reached an age above 36 months.
  • the present invention aims to normalize intestinal microbiota in human subjects preferably with an age above 36 months, preferably an age above 8 years, more preferably an age above 15 years, most preferably above 18 years.
  • Table 1 Additions to the dialysis tube comprising diluted faeces Number Sphingosine GOS Inulin 1 300 ⁇ g 0 0 2 0 103.7 mg 11.5 mg 3 300 ⁇ g 103.7 mg 11.5 mg
  • D-sphingosine was added to the dialysis tubes instead of sphingophospholipid such as sphingomyelin, since degradation of sphingophospholipids in the small intestine gives D-sphingosine.
  • sphingophospholipid such as sphingomyelin
  • the sphingosine was dissolved in ethanol (stock 10 mg/ml). 30 ⁇ l of a stock of 10 mg/ml was added to the dialysis tube.
  • FISH Fluorescence In Situ Hybridisation
  • the Erec482 probe was used ( Franks, A.H., et al., Appl. Environ. Microbiol., 1998. 64(9): p. 3336-3345 ).
  • Bifidobacteria determination the Bif164 probe was used ( Langendijk, P., et al., Appl. Environ. Microbiol., 1995. 61(8): p. 3069-3075 ).
  • the Lab158 probe was used ( Harmsen, H.J.M., et al., Microbial Ecology in Health and Disease, 1999. Volume 11: p. 3-12 ).
  • the Ec1531 probe was used ( Poulsen, L.K., et al., Infect Immun, 1994. 62(11): p. 5191-4 ). Total number of bacteria was determined by DAPI staining. The ratio Finnicutes/Bacteroidetes was set at the percentage of bacteria detected by the Chis150, Clit135, Erec482 and Lab158 probe, divided by the percentage of bacteria divided by the Bac303 probe. The bacteria detected by the Erec482 group are usually the largest group of Firmicutes in the human intestine.
  • the Bac303, Chis150, Clit135, Ec1351 and Lab158 probe all showed signals below the detection limit of FISH, being ⁇ 10 6 cells per gram of sample or a relative abundance lower than I in 1000 cells (0.1 %). In case of the Bac303 the samples were stored under poor conditions, but a faint signal was observed in the samples to which GOS and inulin was added.
  • Clostridia and Eubacteria being the largest group of intestinal Firmicutes, decrease when non-digestible carbohydrates more particular GOS and/or inulin are fermented or when sphingosine is present. When both components are present a further improved effect is observed.
  • Infant nutrition comprising lipid providing 48% of the total calories, protein providing 8% of the total calories and a digestible carbohydrate providing 44% of the total calories;
  • the composition comprises vitamins, trace elements and minerals according to EU directives.
  • the label of the package of this infant nutrition indicates that the nutrition aims to improve the intestinal flora, increase the number of intestinal bifidobacteria, decrease the number of intestinal pathogens and/or to keep a well balanced intestinal flora.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Pediatric Medicine (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Claims (11)

  1. Utilisation d'une composition nutritionnelle comprenant
    A un sphingophospholipide, de préférence la sphingomyéline, et/ou au moins un produit de dégradation de sphingophospholipide choisi dans le groupe consistant en céramide, lysosphingophospholipide, sphingoïde phosphate et base sphingoïde libre, et
    B au moins des fructo-oligosaccharides et des galacto-oligosaccharides,
    pour la fabrication d'une composition pour normaliser le microbiote intestinal chez un sujet humain vers le microbiote trouvé chez des sujets minces sains et/ou des enfants nourris au sein, où la composition du microbiote intestinal est normalisée concernant au moins l'un choisi dans le groupe consistant en un indice prébiotique accru, un rapport Bifidobacteria/bactéries totales accru et un rapport Firmicutes/Bacteroidetes réduit.
  2. Utilisation selon la revendication 1 où ledit sujet humain a un âge inférieur à 36 mois.
  3. Utilisation selon la revendication 1 ou 2 où le microbiote reste normalisé quand ledit sujet humain a atteint un âge supérieur à 36 mois.
  4. Utilisation selon l'une quelconque des revendications précédentes pour la prévention de l'obésité et/ou de l'adiposité, de préférence encore pour l'utilisation chez un sujet humain d'un âge inférieur à 36 mois et pour la prévention de l'obésité et/ou de l'adiposité quand ledit sujet humain a atteint un âge supérieur à 36 mois.
  5. Utilisation selon la revendication 4 pour la prévention d'un trouble choisi dans le groupe consistant en le diabète de type 2, l'hyperglycémie à jeun, la résistance à l'insuline, l'adiposité viscérale, l'hyperinsulinémie, l'hypertension, les maladies cardiovasculaires, les maladies cérébrovasculaires, l'artériosclérose, la dyslipidémie, l'hyperuricémie, la stéatose du foie, l'arthrose et l'apnée du sommeil.
  6. Utilisation selon l'une quelconque des revendications précédentes pour le traitement et/ou la prévention d'une infection gastro-intestinale, de la diarrhée et/ou d'une inflammation gastro-intestinale, d'une allergie, de l'asthme, de la dermatite atopique, de l'eczéma, des infections systémiques et des infections respiratoires.
  7. Utilisation selon l'une quelconque des revendications précédentes où la composition comprend au moins 0,25 % en poids de sphingophospholipide, de préférence de sphingomyéline, et/ou d'au moins un produit de dégradation de sphingophospholipide choisi dans le groupe consistant en céramide, lysosphingophospholipide, sphingoïde phosphate et base sphingoïde libre sur la base des lipides.
  8. Utilisation selon l'une quelconque des revendications précédentes où la composition comprend en outre des oligosaccharides à acide uronique.
  9. Utilisation selon l'une quelconque des revendications précédentes où la composition comprend au moins 0,25 % en poids de fructo-oligosaccharides et galacto-oligosaccharides sur la base du poids sec de la composition.
  10. Utilisation selon l'une quelconque des revendications précédentes où la composition comprend des lipides fournissant 35 à 50 % de calories sur la base des calories totales, des glucides digestibles fournissant 40 à 55 % de calories sur la base des calories totales et des protéines fournissant 7,5 à 12,5 % de calories sur la base des calories totales de la composition.
  11. Utilisation selon l'une quelconque des revendications précédentes où la composition comprend un rapport en poids de sphingophospholipide et/ou de produits de dégradation de celui-ci aux fructo-oligosaccharides et galacto-oligosaccharides entre 0,4 et 200.
EP08865460A 2007-12-21 2008-12-19 Utilisation de la sphingomyéline et de glucides indigestibles pour améliorer la flore intestinale Active EP2234505B1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PL08865460T PL2234505T3 (pl) 2007-12-21 2008-12-19 Zastosowanie sfingomieliny i nietrawionych węglowodanów do poprawy mikroflory jelitowej
EP08865460A EP2234505B1 (fr) 2007-12-21 2008-12-19 Utilisation de la sphingomyéline et de glucides indigestibles pour améliorer la flore intestinale
EP13153122.0A EP2589302B1 (fr) 2007-12-21 2008-12-19 Utilisation de shingomyéline et de glucides non digestibles pour améliorer le microbiote intestinal

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP07124007 2007-12-21
US4078808P 2008-03-31 2008-03-31
EP08153775 2008-03-31
PCT/NL2008/050826 WO2009082216A1 (fr) 2007-12-21 2008-12-19 Utilisation de la sphingomyéline et de glucides indigestibles pour améliorer la flore intestinale
EP08865460A EP2234505B1 (fr) 2007-12-21 2008-12-19 Utilisation de la sphingomyéline et de glucides indigestibles pour améliorer la flore intestinale

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP13153122.0A Division EP2589302B1 (fr) 2007-12-21 2008-12-19 Utilisation de shingomyéline et de glucides non digestibles pour améliorer le microbiote intestinal

Publications (2)

Publication Number Publication Date
EP2234505A1 EP2234505A1 (fr) 2010-10-06
EP2234505B1 true EP2234505B1 (fr) 2013-01-30

Family

ID=40801379

Family Applications (3)

Application Number Title Priority Date Filing Date
EP08865460A Active EP2234505B1 (fr) 2007-12-21 2008-12-19 Utilisation de la sphingomyéline et de glucides indigestibles pour améliorer la flore intestinale
EP13153122.0A Revoked EP2589302B1 (fr) 2007-12-21 2008-12-19 Utilisation de shingomyéline et de glucides non digestibles pour améliorer le microbiote intestinal
EP08865446A Withdrawn EP2229063A1 (fr) 2007-12-21 2008-12-19 Utilisation d'hydrates de carbone non digestibles pour améliorer la flore intestinale

Family Applications After (2)

Application Number Title Priority Date Filing Date
EP13153122.0A Revoked EP2589302B1 (fr) 2007-12-21 2008-12-19 Utilisation de shingomyéline et de glucides non digestibles pour améliorer le microbiote intestinal
EP08865446A Withdrawn EP2229063A1 (fr) 2007-12-21 2008-12-19 Utilisation d'hydrates de carbone non digestibles pour améliorer la flore intestinale

Country Status (8)

Country Link
US (2) US20110034407A1 (fr)
EP (3) EP2234505B1 (fr)
CN (2) CN101951794B (fr)
AR (2) AR077520A1 (fr)
ES (2) ES2611203T3 (fr)
PL (2) PL2234505T3 (fr)
RU (2) RU2478309C2 (fr)
WO (2) WO2009082216A1 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2467031E (pt) 2009-08-18 2014-10-30 Nestec Sa Composição nutricional compreendendo estirpes lactococcus e redução de sintomas de alergia, especialmente em bebés e crianças
CN107510040A (zh) 2010-12-31 2017-12-26 雅培制药有限公司 包含人乳低聚糖和核苷酸的营养型组合物以及其治疗和/或预防肠病毒感染的用途
EP2514435A1 (fr) * 2011-04-19 2012-10-24 Nestec S.A. Formule infantile à utiliser pour la prévention des maladies cardiovasculaires
EP2797606A4 (fr) 2011-08-17 2015-09-30 MicroBiome Therapeutics LLC Composition et utilisation d'une formulation pour augmenter le rapport du microbiote gastro-intestinal du phylum des bacteriodites au microbiote du phylum des firmicutes
JP5827519B2 (ja) * 2011-08-25 2015-12-02 株式会社ダイセル ペルオキシソーム増殖剤応答性受容体活性化剤
CN104039175A (zh) * 2011-10-24 2014-09-10 N·V·努特里奇亚 使用非消化性低聚糖的变态反应疗法
EP2797432A2 (fr) 2011-12-27 2014-11-05 Abbott Laboratories Utilisation d'une formule basses calories pour enfants en bas âge contenant des nucléotides et/ou des caroténoïdes pour réduire les effets négatifs sur la santé plus tard dans la vie
WO2013111823A1 (fr) * 2012-01-25 2013-08-01 株式会社Ｊ－オイルミルズ Procédé de production d'extrait contenant une base sphingoïde
PL2811845T3 (pl) * 2012-02-10 2016-06-30 Nutricia Nv Suplement dla matek wzmacniający układ immunologiczny niemowlęcia
WO2013126015A1 (fr) * 2012-02-23 2013-08-29 N. V. Nutricia Composition comprenant des oligosaccharides non digestibles
SE536599C3 (sv) 2012-04-10 2017-01-10 Hero Ag Näringssammansättning med lågt kalori- och lågt proteininnehåll
CN104968216A (zh) * 2012-12-10 2015-10-07 N·V·努特里奇亚 含有非消化性寡糖的营养组合物
US10028519B2 (en) * 2014-03-05 2018-07-24 Mead Johnson Nutrition Company Nutritional compositions containing ceramide and uses thereof
CA3228950A1 (fr) 2014-07-09 2016-01-14 Dsm Nutritional Products, Llc Compositions d'oligosaccharides et leurs procedes de production
US10835544B2 (en) 2014-12-08 2020-11-17 Glycom A/S Synthetic composition for regulating satiety
US10881674B2 (en) 2014-12-08 2021-01-05 Glycom A/S Synthetic composition for treating metabolic disorders
US10987368B2 (en) 2014-12-08 2021-04-27 Glycom A/S Synthetic composition for preventing or treating CVD
JP6722697B2 (ja) 2015-01-26 2020-07-15 カデナ・バイオ・インコーポレイテッド 動物飼料として使用するためのオリゴ糖組成物及びその生成方法
SG10202103777UA (en) 2015-01-26 2021-05-28 Kaleido Biosciences Inc Glycan therapeutics and related methods thereof
EP3964234A1 (fr) 2015-04-23 2022-03-09 Kaleido Biosciences, Inc. Agents thérapeutiques de glycanes et procédés de traitement
EP3285778A2 (fr) * 2015-04-23 2018-02-28 Kaleido Biosciences, Inc. Régulateurs du microbiome et leurs utilisations associées
RU2724590C2 (ru) 2015-08-04 2020-06-25 Сосьете Де Продюи Нестле С.А. Питательные композиции с 2fl и lnnt для применения при индукции кишечной микробиоты, которая похожа на кишечную микробиоту младенцев на грудном вскармливании
ES2975018T3 (es) * 2015-11-17 2024-07-02 Glycom As Oligosacáridos de la leche humana para el tratamiento de complicaciones asociadas a antibióticos
RU2766014C2 (ru) * 2015-12-14 2022-02-07 Сосьете Де Продюи Нестле С.А. Питательные композиции и детские смеси, способствующие первичной миелинизации
MY186217A (en) 2015-12-15 2021-06-30 Nestle Sa Mixture of hmos
MX2018008954A (es) 2016-01-26 2018-11-09 Nestec Sa Composiciones que comprenden 2fl y lnnt para controlar la ingesta de alimento y el crecimiento en infantes o niños pequeños.
WO2017215721A1 (fr) * 2016-06-15 2017-12-21 Glycom A/S Compositions synthétiques comprenant des oligosaccharides du lait humain pour l'utilisation dans la prévention et le traitement de troubles
US20180030403A1 (en) 2016-07-28 2018-02-01 Bobban Subhadra Devices, systems and methods for the production of humanized gut commensal microbiota
EP3493686B1 (fr) * 2016-08-04 2024-03-27 Société des Produits Nestlé S.A. Compositions nutritives et formules pour nourrissons contenant un mélange d'oligosaccharides et éventuellement bifidobacterium lactis pour prévenir, traiter ou réduire la sévérité des diarrhées non associées au rotavirus
EP3677273B1 (fr) * 2017-08-29 2023-02-08 BGI Shenzhen Bacteroides cellulosityticus et son utilisation pour la prévention et/ou le traitement de l'athérosclérose et l'obésité
JP7576375B2 (ja) 2017-11-03 2024-10-31 カレイド・バイオサイエンシズ・インコーポレイテッド グリカン調製物及び高アンモニア血症のための使用方法
TWI816735B (zh) * 2018-01-18 2023-10-01 日商朝日集團控股股份有限公司 酵母甘露聚糖之用途
CN111698993A (zh) * 2018-02-09 2020-09-22 N·V·努特里奇亚 含有不可消化寡糖的发酵配方物
MX2021005245A (es) 2018-11-08 2021-06-18 Kaleido Biosciences Inc Composiciones de oligosacaridos y metodos de uso de las mismas.
BR112021014094A2 (pt) * 2019-01-18 2021-09-21 Cp Kelco U.S., Inc. Composição prebiótica e uso da mesma
BR112022014436A2 (pt) * 2020-01-31 2022-09-13 Nutricia Nv Método não terapêutico de modulação do tempo e resultado da maturação intestinal em bebês
KR102236944B1 (ko) * 2020-04-29 2021-04-06 (주)네오크레마 갈락토올리고당, 또는 갈락토올리고당 및 콜라겐 트리펩타이드를 포함하는 면역기능 개선 및 피부상태 개선용 기능성 식품조성물 및 화장료 조성물
CN113476463A (zh) * 2021-07-13 2021-10-08 量子高科(广东)生物有限公司 一种益生元组合物及其应用
WO2024056786A1 (fr) 2022-09-14 2024-03-21 N.V. Nutricia Composition nutritionnelle
WO2024056784A1 (fr) 2022-09-14 2024-03-21 N.V. Nutricia Composition nutritionnelle
WO2024156893A1 (fr) 2023-01-27 2024-08-02 N.V. Nutricia Composition nutritionnelle pour améliorer le microbiote intestinal

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4008974B2 (ja) * 1996-12-12 2007-11-14 森永乳業株式会社 ビフィズス菌増殖促進組成物及びその用途
DE19836339B4 (de) 1998-08-11 2011-12-22 N.V. Nutricia Kohlenhydratmischung
JP3544493B2 (ja) * 1999-06-10 2004-07-21 雪印乳業株式会社 乳幼児用栄養組成物
EP1062873A1 (fr) * 1999-12-13 2000-12-27 N.V. Nutricia Aliment amélioré pour bébés, hydrolysat de protéines utilisables dans un tel aliment pour bébés, et procédé de préparation de cet hydrolysat
EP1175905A1 (fr) * 2000-07-24 2002-01-30 Societe Des Produits Nestle S.A. Composition nutritive
GB0229015D0 (en) * 2002-12-12 2003-01-15 Novartis Nutrition Ag New Compound
DE50300428D1 (de) * 2003-01-17 2005-05-12 Link Waldemar Gmbh Co Hüftprothese mit einem in den Markkanal des Oberschenkelknochens zu verankernden Schaft
NL1022443C2 (nl) * 2003-01-20 2004-07-22 Tno Sphingolipiden voor verbetering van de samenstelling van de darmflora.
ATE412767T1 (de) * 2003-10-02 2008-11-15 Nestec Sa Präbiotische effektanalyse
EP1597978A1 (fr) 2004-05-17 2005-11-23 Nutricia N.V. Synergie de GOS et polyfructose
DK1855550T3 (da) * 2005-02-28 2012-01-16 Nutricia Nv Næringspræparat med probiotika
EP1776877A1 (fr) * 2005-10-21 2007-04-25 N.V. Nutricia Méthode de stimulation de la flore intestinale
EP1800675B1 (fr) * 2005-12-23 2011-05-18 N.V. Nutricia Composition comprenant des acides gras polyinsaturés, des protéines, du manganèse et/ou du molybdène et des nucléosides/nucléotides, pour traiter la démence.
CA2634895A1 (fr) * 2005-12-23 2007-06-28 N.V. Nutricia Compositions nutritionnelles destinees a prevenir l'obesite
EP1803358A1 (fr) 2005-12-28 2007-07-04 Laboratorios Ordesa, S.L Formule à effet immunologique pour nourrisson.

Also Published As

Publication number Publication date
CN101951794B (zh) 2016-11-02
EP2234505A1 (fr) 2010-10-06
RU2010130468A (ru) 2012-01-27
AR077520A1 (es) 2011-09-07
ES2402687T3 (es) 2013-05-07
EP2229063A1 (fr) 2010-09-22
EP2589302A1 (fr) 2013-05-08
PL2589302T3 (pl) 2017-05-31
AR071550A1 (es) 2010-06-30
ES2611203T3 (es) 2017-05-05
WO2009082216A1 (fr) 2009-07-02
RU2608215C2 (ru) 2017-01-17
WO2009082214A1 (fr) 2009-07-02
RU2012155333A (ru) 2014-06-27
PL2234505T3 (pl) 2013-06-28
EP2589302B1 (fr) 2016-11-23
CN101951794A (zh) 2011-01-19
RU2478309C2 (ru) 2013-04-10
US20110009359A1 (en) 2011-01-13
US20110034407A1 (en) 2011-02-10
CN101945589A (zh) 2011-01-12

Similar Documents

Publication Publication Date Title
EP2234505B1 (fr) Utilisation de la sphingomyéline et de glucides indigestibles pour améliorer la flore intestinale
US8715769B2 (en) Preventing diseases in infants delivered via caesarean section
AU2014278835B2 (en) Synbiotic composition for treatment of infections in allergic patients
DK1571923T3 (en) PREBIOTIC COMPOSITIONS
EP1957084B1 (fr) Préparation contenant des oligosaccharides pour le traitement prophylactique/thérapeutique de la fiebre et des crises hyperpyrétiques
PT1855550E (pt) Composição nutricional com probióticos
BRPI0813391B1 (pt) composição para lactente e/ ou criança na primeira infância com oligossacarídeos não digeríveis e bifidobactéria não viável, e, usos da mesma
JP2011503225A (ja) シンバイオティクス組成物

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100618

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BOEHM, GUENTHER

Inventor name: BEERMANN, CHRISTOPHER

Inventor name: VAN DER BEEK, ELINE MARLEEN

Inventor name: KNOL, JAN

Inventor name: BEN AMOR, KAOUTHER

Inventor name: NIEUWENHUIZEN, WILLEM FERDINAND

DAX Request for extension of the european patent (deleted)
RIN1 Information on inventor provided before grant (corrected)

Inventor name: SPEELMANS, GELSKE

Inventor name: BEERMANN, CHRISTOPHER

Inventor name: VAN DER BEEK, ELINE MARLEEN

Inventor name: KNOL, JAN

Inventor name: BEN AMOR, KAOUTHER

Inventor name: NIEUWENHUIZEN, WILLEM FERDINAND

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 595535

Country of ref document: AT

Kind code of ref document: T

Effective date: 20130215

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602008022025

Country of ref document: DE

Effective date: 20130321

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2402687

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20130507

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: PL

Ref legal event code: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130130

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130530

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130130

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130430

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130530

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130130

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130130

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130130

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130501

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130130

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130130

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130130

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130130

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130130

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20131031

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602008022025

Country of ref document: DE

Effective date: 20131031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20081219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130130

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 8

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 9

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20191212

Year of fee payment: 12

Ref country code: IE

Payment date: 20191219

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20191202

Year of fee payment: 12

Ref country code: BE

Payment date: 20191223

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20191223

Year of fee payment: 12

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20210101

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 595535

Country of ref document: AT

Kind code of ref document: T

Effective date: 20201219

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20201231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201219

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201219

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230513

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20231219

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20231130

Year of fee payment: 16

Ref country code: IT

Payment date: 20231221

Year of fee payment: 16

Ref country code: FR

Payment date: 20231226

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20240118

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20231227

Year of fee payment: 16

Ref country code: CH

Payment date: 20240101

Year of fee payment: 16